NCT01170663 · OUTCOME

Cmin Prior to 4th Ramucirumab (IMC-1211B) Infusion

A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma · Source last updated 2019-09-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: GEOMETRIC_MEAN
Unit: µg/mL
Interval / dispersion: Geometric Coefficient of Variation
Time frame: Cycle 2, Day 15 (28-day cycle)

Analysis population: All participants who received Ramucirumab (IMC-1121B) plus Paclitaxel and had Cmin observations at specific timepoint.

Groups in this outcome

Ramucirumab (IMC-1211B) Plus Paclitaxel

8 mg/kg of ramucirumab (IMC-1121B) was administered by IV infusion on Days 1 and 15 in combination with 80 mg/m² paclitaxel administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Ramucirumab (IMC-1211B) Plus Paclitaxel	203

Reported measurements

Source class 1

Values in µg/mL · Interval/dispersion: Geometric Coefficient of Variation
Group	Value	Spread	Lower	Upper	Comment
Ramucirumab (IMC-1211B) Plus Paclitaxel	45.0	50	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
spread
50
value
45.0

denoms

counts
group Id
OG000
value
203
units
Participants

dispersion Type

Geometric Coefficient of Variation

groups

description
8 mg/kg of ramucirumab (IMC-1121B) was administered by IV infusion on Days 1 and 15 in combination with 80 mg/m² paclitaxel administered by IV infusion on Days 1, 8, and 15 of a 28-day cycle.
id
OG000
title
Ramucirumab (IMC-1211B) Plus Paclitaxel

param Type

GEOMETRIC_MEAN

population Description

All participants who received Ramucirumab (IMC-1121B) plus Paclitaxel and had Cmin observations at specific timepoint.

reporting Status

POSTED

time Frame

Cycle 2, Day 15 (28-day cycle)

title

Cmin Prior to 4th Ramucirumab (IMC-1211B) Infusion

type

SECONDARY

unit Of Measure

µg/mL

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice